Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3ζ protein and represses lung cancer metastasis

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454. doi:10.1038/nature25183.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Adjei AA. New strategies to develop new medications for lung cancer and metastasis. Cancer Metastasis Rev. 2015;34(2):265–275. doi:10.1007/s10555-015-9553-5.
   PubMed Web of Science ®Google Scholar
• Shroff GS, Viswanathan C, Carter BW, Benveniste MF, Truong MT, Sabloff BS. Staging lung cancer: metastasis. Radiol Clin North Am. 2018;56(3):411–418. doi:10.1016/j.rcl.2018.01.009.
   PubMed Web of Science ®Google Scholar
• Popper HH. Progression and metastasis of lung cancer. Cancer Metastasis Rev. 2016;35(1):75–91. doi:10.1007/s10555-016-9618-0.
   PubMed Web of Science ®Google Scholar
• Cho YJ, Cho YM, Kim SH, Shin KH, Jung ST, Kim HS. Clinical analysis of patients with skeletal metastasis of lung cancer. BMC Cancer. 2019;19(1):303. doi:10.1186/s12885-019-5534-3.
   PubMedGoogle Scholar
• Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 1994;79(1):13–21. doi:10.1016/0092-8674(94)90396-4.
   PubMed Web of Science ®Google Scholar
• Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment. Nat Med. 2014;20(11):1242–1253. 10.1038/nm.3739.
   PubMed Web of Science ®Google Scholar
• Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67(1):425–479. doi:10.1146/annurev.biochem.67.1.425.
   PubMedGoogle Scholar
• Mustachio LM, Lu Y, Kawakami M, Roszik J, Freemantle SJ, Liu X, Dmitrovsky E. Evidence for the ISG15-specific deubiquitinase USP18 as an antineoplastic target. Cancer Res. 2018;78(3):587–592. doi:10.1158/0008-5472.CAN-17-1752.
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhang DE. Interferon-stimulated gene 15 and the protein ISGylation system. J Interferon Cytokine Res. 2011;31(1):119–130. doi:10.1089/jir.2010.0110.
   PubMed Web of Science ®Google Scholar
• Komander D, Clague MJ, Urbe S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol. 2009;10(8):550–563. doi:10.1038/nrm2731.
   PubMed Web of Science ®Google Scholar
• Harrigan JA, Jacq X, Martin NM, Jackson SP. Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018;17(1):57–78. doi:10.1038/nrd.2017.152.
   PubMed Web of Science ®Google Scholar
• Honke N, Shaabani N, Zhang DE, Hardt C, Lang KS. Multiple functions of USP18. Cell Death Dis. 2016;7(11):e2444. doi:10.1038/cddis.2016.326.
   PubMed Web of Science ®Google Scholar
• Potu H, Sgorbissa A, Brancolini C. Identification of USP18 as an important regulator of the susceptibility to IFN-alpha and drug-induced apoptosis. Cancer Res. 2010;70(2):655–665. doi:10.1158/0008-5472.CAN-09-1942.
   PubMed Web of Science ®Google Scholar
• Sgorbissa A, Tomasella A, Potu H, Manini I, Brancolini C. Type I IFNs signaling and apoptosis resistance in glioblastoma cells. Apoptosis. 2011;16(12):1229–1244. doi:10.1007/s10495-011-0639-4.
   PubMed Web of Science ®Google Scholar
• Yan M, Luo JK, Ritchie KJ, Sakai I, Takeuchi K, Ren R, Zhang DE. Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling. Blood. 2007;110(1):305–312. doi:10.1182/blood-2006-07-033209.
   PubMed Web of Science ®Google Scholar
• Diao W, Guo Q, Zhu C, Song Y, Feng H, Cao Y, Du M, Chen H. USP18 promotes cell proliferation and suppressed apoptosis in cervical cancer cells via activating AKT signaling pathway. BMC Cancer. 2020;20(1):741. doi:10.1186/s12885-020-07241-1.
   PubMed Web of Science ®Google Scholar
• Huang F, Zheng C, Huang L, Lin C, Wang J. USP18 directly regulates Snail1 protein through ubiquitination pathway in colorectal cancer. Cancer Cell Int. 2020;20(1):346. doi:10.1186/s12935-020-01442-1.
   PubMed Web of Science ®Google Scholar
• Feng L, Wang K, Tang P, Chen S, Liu T, Lei J, Yuan R, Hu Z, Li W, Yu X. Deubiquitinase USP18 promotes the progression of pancreatic cancer via enhancing the Notch1-c-Myc axis. Aging (Albany NY). 2020;12(19):19273–19292. doi:10.18632/aging.103760.
   PubMedGoogle Scholar
• Guo Y, Chinyengetere F, Dolinko AV, Lopez-Aguiar A, Lu Y, Galimberti F, Ma T, Feng Q, Sekula D, Freemantle SJ, et al. Evidence for the ubiquitin protease UBP43 as an antineoplastic target. Mol Cancer Ther. 2012;11(9):1968–1977. doi:10.1158/1535-7163.MCT-12-0248.
   PubMed Web of Science ®Google Scholar
• Guo Y, Dolinko AV, Chinyengetere F, Stanton B, Bomberger JM, Demidenko E, Zhou DC, Gallagher R, Ma T, Galimberti F, et al. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARalpha and inhibits the growth of acute promyelocytic leukemia. Cancer Res. 2010;70(23):9875–9885. doi:10.1158/0008-5472.CAN-10-1100.
   PubMed Web of Science ®Google Scholar
• Mustachio LM, Lu Y, Tafe LJ, Memoli V, Rodriguez-Canales J, Mino B, Villalobos PA, Wistuba I, Katayama H, Hanash SM, et al. Deubiquitinase USP18 loss mislocalizes and destabilizes KRAS in lung cancer. Mol Cancer Res. 2017;15(7):905–914. doi:10.1158/1541-7786.MCR-16-0369.
   PubMed Web of Science ®Google Scholar
• Cai X, Feng S, Zhang J, Qiu W, Qian M, Wang Y. USP18 deubiquitinates and stabilizes Twist1 to promote epithelial-mesenchymal transition in glioblastoma cells. Am J Cancer Res. 2020;10(4):1156–1169.
   PubMed Web of Science ®Google Scholar
• Mhawech P. 14-3-3 proteins–an update. Cell Res. 2005;15(4):228–236. doi:10.1038/sj.cr.7290291.
   PubMed Web of Science ®Google Scholar
• Tzivion G, Gupta VS, Kaplun L, Balan V. 14-3-3 proteins as potential oncogenes. Semin Cancer Biol. 2006;16(3):203–213. doi:10.1016/j.semcancer.2006.03.004.
   PubMed Web of Science ®Google Scholar
• Niemantsverdriet M, Wagner K, Visser M, Backendorf C. Cellular functions of 14-3-3 zeta in apoptosis and cell adhesion emphasize its oncogenic character. Oncogene. 2008;27(9):1315–1319. doi:10.1038/sj.onc.1210742.
   PubMed Web of Science ®Google Scholar
• Tong S, Xia T, Fan K, Jiang K, Zhai W, Li JS, Wang SH, Wang JJ. Loss of Par3 promotes lung adenocarcinoma metastasis through 14-3-3zeta protein. Oncotarget. 2016;7(39):64260–64273. doi:10.18632/oncotarget.11728.
   PubMedGoogle Scholar
• Tong S, Xia T, Fan K, Jiang K, Zhai W, Li JS, Wang SH, Wang JJ. 14-3-3zeta promotes lung cancer cell invasion by increasing the Snail protein expression through atypical protein kinase C (aPKC)/NF-kappaB signaling. Exp Cell Res. 2016;348(1):1–9. doi:10.1016/j.yexcr.2016.08.014.
   PubMed Web of Science ®Google Scholar
• Zhao GY, Ding JY, Lu CL, Lin ZW, Guo J, Guo J, Ge D. The overexpression of 14-3-3zeta and Hsp27 promotes non-small cell lung cancer progression. Cancer. 2014;120(5):652–663. doi:10.1002/cncr.28452.
   PubMed Web of Science ®Google Scholar
• Choi JE, Hur W, Jung CK, Piao LS, Lyoo K, Hong SW, Kim SW, Yoon HY, Yoon SK. Silencing of 14-3-3zeta over-expression in hepatocellular carcinoma inhibits tumor growth and enhances chemosensitivity to cis-diammined dichloridoplatium. Cancer Lett. 2011;303(2):99–107. doi:10.1016/j.canlet.2011.01.015.
   PubMed Web of Science ®Google Scholar
• Jang JS, Cho HY, Lee YJ, Ha WS, Kim HW. The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol Res. 2004;14(10):491–499. doi:10.3727/0965040042380441.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhao J, Du Y, Park HR, Sun SY, Bernal-Mizrachi L, Aitken A, Khuri FR, Fu H. Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci U S A. 2008;105(1):162–167. doi:10.1073/pnas.0710905105.
   PubMed Web of Science ®Google Scholar
• Neal CL, Yao J, Yang W, Zhou X, Nguyen NT, Lu J, Danes CG, Guo H, Lan KH, Ensor J, et al. 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res. 2009;69(8):3425–3432. doi:10.1158/0008-5472.CAN-08-2765.
   PubMed Web of Science ®Google Scholar
• Zhao C, Denison C, Huibregtse JM, Gygi S, Krug RM. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci U S A. 2005;102(29):10200–10205. doi:10.1073/pnas.0504754102.
   PubMed Web of Science ®Google Scholar
• Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5(1):5241. doi:10.1038/ncomms6241.
   PubMed Web of Science ®Google Scholar
• Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, Demidenko E, Korc M, Shi W, Preis M, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest. 2010;120(4):1298–1309. doi:10.1172/JCI39566.
   PubMed Web of Science ®Google Scholar
• Kawakami M, Mustachio LM, Rodriguez-Canales J, Mino B, Roszik J, Tong P, Wang J, Lee JJ, Myung JH, Heymach JV, et al. Next-generation CDK2/9 inhibitors and anaphase catastrophe in lung cancer. J Natl Cancer Inst. 2017;109. doi:10.1093/jnci/djw297.
   Google Scholar
• Buel GR, Chen X, Chari R, O’Neill MJ, Ebelle DL, Jenkins C, Sridharan V, Tarasov SG, Tatasova NI, Andresson T, et al. Structure of E3 ligase E6AP with a proteasome-binding site provided by substrate receptor hRpn10. Nat Commun. 2020;11(1):1291. doi:10.1038/s41467-020-15073-7.
   PubMed Web of Science ®Google Scholar
• Wilsker DF, Barrett AM, Dull AB, Lawrence SM, Hollingshead MG, Chen A, Kummar S, Parchment RE, Doroshow JH, Kinders RJ. Evaluation of pharmacodynamic responses to cancer therapeutic agents using DNA damage markers. Clin Cancer Res. 2019;25(10):3084–3095. doi:10.1158/1078-0432.CCR-18-2523.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Qiao W, Wang X, Yin H, Cui J, Cui Y, Chen X, Hu J, Lu H, Meng Q, et al. 14-3-3ζ/TGFβR1 promotes tumor metastasis in lung squamous cell carcinoma. Oncotarget. 2016;7(50):82972–82984. doi:10.18632/oncotarget.12690.
   PubMedGoogle Scholar
• Zou W, Wang J, Zhang DE. Negative regulation of ISG15 E3 ligase EFP through its autoISGylation. Biochem Biophys Res Commun. 2007;354(1):321–327. 10.1016/j.bbrc.2006.12.210.
   PubMed Web of Science ®Google Scholar
• Fu H, Subramanian RR, Masters SC. 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol. 2000;40(1):617–647. doi:10.1146/annurev.pharmtox.40.1.617.
   PubMedGoogle Scholar
• Yang X, Cao W, Zhang L, Zhang W, Zhang X, Lin H. Targeting 14-3-3zeta in cancer therapy. Cancer Gene Ther. 2012;19(3):153–159. 10.1038/cgt.2011.85.
   PubMed Web of Science ®Google Scholar
• Bridges D, Moorhead GB. 14-3-3 proteins: a number of functions for a numbered protein. Sci STKE. 2005;2005(296):re10. doi:10.1126/stke.2962005re10.
   PubMedGoogle Scholar
• Pennington KL, Chan TY, Torres MP, Andersen JL. The dynamic and stress-adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and context-dependent protein-protein interactions. Oncogene. 2018;37(42):5587–5604. doi:10.1038/s41388-018-0348-3.
   PubMed Web of Science ®Google Scholar
• Cui J, Song Y, Han X, Hu J, Chen Y, Chen X, Xu X, Xing Y, Lu H, Cai L. Targeting 14-3-3ζ overcomes resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in lung adenocarcinoma via BMP2/Smad/ID1 signaling. Front Oncol. 2020;10:542007. doi:10.3389/fonc.2020.542007.
   PubMed Web of Science ®Google Scholar
• Woodcock JM, Murphy J, Stomski FC, Berndt MC, Lopez AF. The dimeric versus monomeric status of 14-3-3zeta is controlled by phosphorylation of Ser58 at the dimer interface. J Biol Chem. 2003;278(38):36323–36327. doi:10.1074/jbc.M304689200.
   PubMed Web of Science ®Google Scholar
• Mortenson JB, Heppler LN, Banks CJ, Weerasekara VK, Whited MD, Piccolo SR, Johnson WE, Thompson JW, Andersen JL. Histone deacetylase 6 (HDAC6) promotes the pro-survival activity of 14-3-3ζ via deacetylation of lysines within the 14-3-3ζ binding pocket. J Biol Chem. 2015;290(20):12487–12496. doi:10.1074/jbc.M114.607580.
   PubMed Web of Science ®Google Scholar
• Xing C, Lu XX, Guo PD, Shen T, Zhang S, He XS, Gan WJ, Li XM, Wang JR, Zhao YY, et al. Ubiquitin-specific protease 4-mediated deubiquitination and stabilization of PRL-3 is required for potentiating colorectal oncogenesis. Cancer Res. 2016;76(1):83–95. doi:10.1158/0008-5472.CAN-14-3595.
   PubMed Web of Science ®Google Scholar
• Basters A, Geurink PP, Rocker A, Witting KF, Tadayon R, Hess S, Semrau MS, Storici P, Ovaa H, Knobeloch KP, et al. Structural basis of the specificity of USP18 toward ISG15. Nat Struct Mol Biol. 2017;24(3):270–278. doi:10.1038/nsmb.3371.
   PubMed Web of Science ®Google Scholar